{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T20:49:28Z","timestamp":1788122968277,"version":"build-2803163510"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 75-year-old man, treated with curative intent for histopathologically proven prostate cancer (initial prostate-specific antigen, 27 ng\/mL; Gleason 4 + 5 = 9) through external beam radiation therapy in 2010 in combination with 3 years of androgen deprivation therapy (leuprorelin), underwent <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT for biochemical recurrence with a prostate-specific antigen of 4.1 ng\/mL in February 2019. Multiple pelvic and some para-aortic lymph nodes showed highly increased <jats:sup>18<\/jats:sup>F-DCFPyL uptake, suspicious for metastases. Incidentally, a solid mesenteric mass and mesenteric lymph nodes with moderately increased <jats:sup>18<\/jats:sup>F-DCFPyL uptake were found. Upon histopathological evaluation, this proved to be a low-grade follicular lymphoma.<\/jats:p>","DOI":"10.1097\/rlu.0000000000002738","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T16:22:09Z","timestamp":1564417329000},"page":"e96-e97","source":"Crossref","is-referenced-by-count":3,"title":["18F-DCFPyL Uptake in an Incidentally Detected Follicular Lymphoma by PET\/CT Performed for Biochemically Recurrent Prostate Cancer"],"prefix":"10.1097","volume":"45","author":[{"given":"Dennie","family":"Meijer","sequence":"first","affiliation":[{"name":"Department of Urology, Amsterdam University Medical Centers, Location VU Medical Center, Amsterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurits","family":"Wondergem","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Location Alkmaar, Alkmaar, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remco J.J.","family":"Knol","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Location Alkmaar, Alkmaar, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter A.M.","family":"Broos","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Location Alkmaar, Alkmaar, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friso M.","family":"van der Zant","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Location Alkmaar, Alkmaar, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","article-title":"Prostate-specific membrane antigen expression as a predictor of prostate cancer progression","volume":"38","year":"2007","journal-title":"Hum Pathol"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/S0022-5347(05)67511-8","article-title":"Prostate specific antigen only progression of prostate cancer","volume":"163","year":"2000","journal-title":"J Urol"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib4-20230925","first-page":"786","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib5-20230925","first-page":"45","article-title":"68Ga-PSMA PET in advanced prostate cancer updated diagnostic utility, sensitivity and specificity and distribution of PSMA-avid lesions systematic review and meta-analysis","volume":"123","year":"2019","journal-title":"BJU Int"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","article-title":"2-(3-{1-carboxy-5-[(6-[18F]Fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer","volume":"17","year":"2011","journal-title":"Clin Cancer Res"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial evaluation of [F-18]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer","volume":"17","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/pcan.2016.13","article-title":"PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges","volume":"19","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/RLU.0000000000001169","article-title":"Follicular lymphoma showing avid uptake on Ga-68 PSMA-HBED-CC PET\/CT","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2967\/jnumed.117.190215","article-title":"Detection of synchronous primary malignancies with Ga-68-labeled prostate-specific membrane antigen PET\/CT in patients with prostate cancer: frequency in 764 patients","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/RLU.0000000000001378","article-title":"Prostate-specific membrane antigen uptake in small cleaved B-Cell follicular non-Hodgkin lymphoma","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib12-20230925","first-page":"3192","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","year":"1999","journal-title":"Cancer Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:06:38Z","timestamp":1695621998000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,30]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002738","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,30]]}}}